Recently, although immunotherapies represented by anti-CTLA-4 antibodies and PD1/PD-L1 antibodies have made their debut in anti-cancer clinical practice(Xin Yu et al. 2020), the lack of universally accepted paradigm for the immune escape of cancer is one of the reasons limiting the effect of immunotherapies. Here, CTLA4 is linked to cancer.